Molecular brace traps two cancer-driving proteins to suppress prostate cancer growth in preclinical tests
Many modern cancer drugs typically target a specific protein or signaling pathway to treat tumors. Now, researchers at the University of Michigan Health Rogel Cancer Center are taking a new approach by throwing a molecular wrench into the machinery driving prostate cancer. In preclinical studies, this new approach demonstrated greater antitumor activity while sparing normal cells.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
